Aurobindo Pharma Launches Generic Advair Diskus Inhaler in US Market
Aurobindo Pharma's subsidiary, Lannett Company LLC, has launched a generic version of GSK's Advair Diskus in the US, marking the company's entry into the complex inhalation market. Available in 100/50 mcg and 250/50 mcg strengths, the product treats asthma and chronic obstructive pulmonary disease. This launch is the first from Aurobindo's inhalation pipeline and expands its portfolio beyond oral generics. The US market for this drug is valued at approximately $908 million, with competitors like Cipla also entering the space.
First-hand measurement across 5 sources
We measured how 5 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (56/100). Lens Score 38/100.
Outlets measured: thehindu, economictimes, economictimes, news18, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 31 Aug, 08:26 am. Other outlets followed.